Guggenheim analyst Yatin Suneja initiated coverage of MoonLake Immunotherapeutics with a Buy rating and $51 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MLTX:
- MoonLake Immunotherapeutics added to Best Ideas List at Wedbush
- MoonLake price target raised to $30 from $28 at H.C. Wainwright
- MoonLake Immunotherapeutics management to meet with Piper Sandler
- MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
- Cantor biopharma/biotech analysts hold analyst/industry conference call